KNSA vs ALKS
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
KNSA · Kiniksa Pharmaceuticals International$93.86 ▲ 6.25%
ALKS · Alkermes$45.90 ▲ 3.05%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- KNSA +137.6%
- ALKS +40.6%
Head to head
| Metric | KNSA | ALKS |
|---|---|---|
| Price | $93.86 | $45.90 |
| Change today | ▲ 6.25% | ▲ 3.05% |
| Market cap | $7.37B | $7.71B |
| Return, 3 months | +22.6% | -7.1% |
| Return, year to date | +127.5% | +64.0% |
| Return, 1 year | +144.6% | +39.6% |
| P/E (TTM) | 71.1 | – |
| P/B | 10.4 | 4.1 |
| P/E percentile vs own 5y | 75th | 97th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +58.1% | +27.0% |
| Net profit growth (YoY) | +156.8% | -99.4% |
| Gross margin | 54.3% | 84.6% |
| Operating margin | 13.8% | 8.6% |
| Net margin | 11.6% | 4.0% |
| Return on equity | 17.6% | 3.9% |
| Analyst target vs. price | +13.1% | +30.3% |
| Analyst buy share | 100% | 73% |
| RSI (14) | 60 | 60 |
| 30-day volatility | 78.2% | 31.6% |
| Max drawdown, 1 year | -21.1% | -29.2% |
| Trend read | Strong uptrend | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- ALKS is the largest of the group by market value.
- KNSA has returned the most over the past year.
- KNSA is growing revenue fastest.
- KNSA keeps the most profit per dollar of sales.
- ALKS has been the calmest stock over the last 30 days.